Teva: 'Fierce focus on growth'

by John McCamant, editor The Medical technology Stock Letter

While the stock market is reeling, valuations are becoming unusually inexpensive and this is providing excellent opportunities for cool-headed investors.

Israel-based Teva Pharmaceuticals (TEVA) -- our latest buy recommendation -- offers diversification for our portfolios. It is a dynamic company with a fierce focus on growth.